Fevertree has announced a strategic partnership with global beverage company, Molson Coors, to help drive growth in the US. Molson Coors is set to buy an 8.5% stake in Fevertree for £71mn, which it will return to shareholders in the form of share buybacks, beginning in February 2025.
Fevertree’s also seen full-year revenue rise by 2% to £368mn, ignoring the impact of exchange rates. This was driven by double-digit growth in the US and the Rest of the World, which helped to offset declines in the UK.
The group expects a “strong uplift” in underlying cash profit (EBITDA) when it reports last year’s results. Market expectations currently sit at around £50.8mn.
In 2025, revenue is expected to grow at a low single-digit rate, while increased marketing spend in the US will have a short-term impact on cash profits. In 2026, revenue and cash profits are both expected to grow at double-digit rates.
The shares rose 15.3% in early trading.
Our view
HL view to follow.
Fevertree key facts
All ratios are sourced from Refinitiv, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.
This article is not advice or a recommendation to buy, sell or hold any investment.No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment.This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication.Non - independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place(including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing.Please see our full non - independent research disclosure for more information.